WILLIAM V HARRER M.D. NPI 1972584217

NPI Details

William V Harrer, M.D. is a medical oncology internal medicine in Sequim, WA with 37 years of experience. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. William V Harrer, M.D. NPI is 1972584217. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: JEFFERSON MEDICAL COLLEGE OF THOMAS JEFFERSON UNIVERSITY
Graduation Year:1989

The provider's business location address is:

844 N 5TH AVE
SEQUIM, WA
ZIP 98382-045
Phone: (360) 839-8953
Fax: (605) 825-6143

The NPI 1972584217 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, epoetin alfa, (for non-esrd use), 1000 units (HCPCS:J0885)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units (HCPCS:Q5106)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Ferritin (blood protein) level (HCPCS:82728)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection, pegfilgrastim-bmez, biosimilar, (ziextenzo), 0.5 mg (HCPCS:Q5120)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional (HCPCS:99211)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Blood test, clotting time (HCPCS:85610)
• Injection of drug or substance into vein (HCPCS:96374)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Follow-up hospital inpatient care per day, typically 15 minutes (HCPCS:99231)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Red blood count, manual test (HCPCS:85044)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Folic acid level, serum (HCPCS:82746)
• Injection, methylprednisolone sodium succinate, up to 40 mg (HCPCS:J2920)
• Initial hospital inpatient care per day, typically 50 minutes (HCPCS:99222)
• New patient office or other outpatient visit, 30-44 minutes (HCPCS:99203)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Protein measurement, serum (HCPCS:84165)
• Red blood count, automated test (HCPCS:85045)
• Drawing of blood for a medical problem (HCPCS:99195)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Magnesium level (HCPCS:83735)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Established patient office or other outpatient visit, 10-19 minutes (HCPCS:99212)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Measurement of immunoglobulin light chains (HCPCS:83521)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Beta-2 microglobulin (protein) level (HCPCS:82232)

The enumeration date for this NPI number is 11/11/2005 and was last updated on 10/12/2023.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.